Biopharma | January 11, 2026
InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The approval is backed by data showing deep, durable responses and manageable tolerability
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
Subscribe To Our Newsletter & Stay Updated
